IGC Pharma to Showcase Alzheimer's Treatments at BIO Partnering @ JPM 2025
Key Insights
IGC Pharma (search) will participate in BIO Partnering @ JPM during the J.P. Morgan Healthcare Conference in January 2025 to present its Alzheimer's disease (search) treatments.
The company will hold one-on-one meetings with investors and pharmaceutical firms to highlight its business strategy and recent advancements.
IGC Pharma (search)'s portfolio includes IGC-AD1, a cannabinoid-based therapy in Phase 2 trials for agitation in dementia (search) related to Alzheimer's disease (search).
IGC Pharma (search), Inc. (NYSE American: IGC), a biotechnology company focused on developing treatments for Alzheimer's disease (search), announced its participation in BIO Partnering @ JPM, which is scheduled alongside the J.P. Morgan 43rd Annual Healthcare Conference in January 2025. The company's management team will be available for both in-person and virtual meetings to discuss its business strategy, recent achievements, and upcoming milestones.
IGC Pharma (search) will engage in one-on-one meetings with registered investors and pharmaceutical companies from January 13-16, 2025. These meetings will provide a platform to showcase IGC Pharma's innovative approaches to Alzheimer's treatment, including its AI-powered drug discovery platform and clinical-stage assets.
Focus on Alzheimer's Disease Therapeutics
IGC Pharma (search)'s pipeline includes IGC-AD1, a cannabinoid-based treatment currently undergoing a Phase 2 clinical trial (NCT05543681) for agitation in dementia (search) associated with Alzheimer's. Clinical data for IGC-AD1 has suggested potential for faster-acting and more effective relief compared to traditional medications for agitation, a common and distressing symptom for Alzheimer's patients.
In addition to IGC-AD1, IGC Pharma (search) is developing the TGR family of compounds, including TGR-63, which targets amyloid plaques (search), a key pathological hallmark of Alzheimer's disease (search). The company's IGC-C and IGC-M platforms are in preclinical development, focusing on metabolic disorders, tau proteins, early plaque formation, and other disease hallmarks associated with Alzheimer's.
AI-Driven Innovation
IGC Pharma (search) is leveraging artificial intelligence to enhance its drug discovery and development efforts. The company's AI models are designed to predict potential biomarkers for the early detection of Alzheimer's, optimize clinical trials, and predict receptor affinity, among other applications. This AI-driven approach aims to accelerate the development of more effective treatments for Alzheimer's disease (search) and improve patient outcomes.
Management Commentary
"We are excited to participate in BIO Partnering @ JPM and share our progress in developing innovative treatments for Alzheimer's disease (search)," said [Name and Title of IGC Pharma (search) spokesperson]. "This event provides a valuable opportunity to connect with potential partners and investors who share our commitment to transforming patient care in Alzheimer's and related conditions."
IGC Pharma (search) will also host concurrent one-on-one meetings in San Francisco during JPM Week. Interested parties are encouraged to contact igc@imsinvestorrelations.com to schedule a meeting.